Alzamend Neuro, Inc.
ALZN
$2.22
-$0.14-5.93%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.29M | 3.08M | 3.06M | 3.22M | 3.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.23M | 4.50M | 4.21M | 5.83M | 7.37M |
| Operating Income | -6.23M | -4.50M | -4.21M | -5.83M | -7.37M |
| Income Before Tax | -6.24M | -4.51M | -4.23M | -5.85M | -7.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.24 | -4.51 | -4.23 | -5.85 | -7.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.24M | -4.51M | -4.23M | -5.85M | -7.39M |
| EBIT | -6.23M | -4.50M | -4.21M | -5.83M | -7.37M |
| EBITDA | -6.17M | -4.45M | -4.16M | -5.78M | -7.32M |
| EPS Basic | -9.02 | -19.16 | -27.86 | -60.13 | -96.37 |
| Normalized Basic EPS | -5.03 | -11.37 | -17.33 | -37.50 | -60.23 |
| EPS Diluted | -9.02 | -19.16 | -27.86 | -60.13 | -96.37 |
| Normalized Diluted EPS | -5.03 | -11.37 | -17.33 | -37.50 | -60.23 |
| Average Basic Shares Outstanding | 3.82M | 1.80M | 1.17M | 632.60K | 313.10K |
| Average Diluted Shares Outstanding | 3.82M | 1.80M | 1.17M | 632.60K | 313.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |